Compass Therapeutics Investor Presentation Deck

CTX-009 Development Plans Initiated Q4 2022 Phase 2 study in third- and fourth- line colorectal cancer in the US COMPASS THERAPEUTICS Initiate Q1 2023 Phase 2/3 Randomized BTC study in the US O Initiate H2 2023 Phase 2 study in advanced ovarian or other cancer in the US Evaluating additional indications for CTX-009 both as a monotherapy and in combination with chemotherapy 28

View entire presentation